Hillingdon Hospital, Uxbridge, UK
St Mark's Hospital, Harrow, UK.
Clin Med (Lond). 2021 Mar;21(2):135-139. doi: 10.7861/clinmed.2021-0080.
Ulcerative colitis is a relapsing and remitting disease that is increasing in incidence and prevalence. Management aims to achieve rapid resolution of symptoms, mucosal healing and improvement in a patient's quality of life. 5-aminosalicylate acid medications remain the first-line treatment for mild to moderate disease. In the event of suboptimal response to these medications, escalation to immunosuppressive medications and biologics may be necessary. Importantly, despite best medical therapy, surgery may be required in a proportion of patients. The future will likely see an array of new therapeutic options for those with ulcerative colitis with the potential for a more personalised treatment approach.
溃疡性结肠炎是一种复发和缓解的疾病,其发病率和患病率正在增加。治疗的目的是迅速缓解症状、黏膜愈合和改善患者的生活质量。5-氨基水杨酸药物仍然是轻度至中度疾病的一线治疗药物。如果这些药物治疗效果不理想,可能需要升级为免疫抑制剂和生物制剂。重要的是,尽管进行了最佳的药物治疗,仍有一部分患者可能需要手术。对于溃疡性结肠炎患者,未来可能会有一系列新的治疗选择,从而有可能采用更个性化的治疗方法。